Hamostaseologie 2019; 39(03): 266-271
DOI: 10.1055/s-0039-1684032
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia

Michele P. Lambert
1  Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2  Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
› Author Affiliations
Further Information

Publication History

06 September 2018

14 February 2019

Publication Date:
05 June 2019 (eFirst)

Abstract

Management of immune thrombocytopenia (ITP) is complex requiring communication between patients and caregivers to establish a mutual understanding of the impact of the patient's disease on quality of life, the current symptoms and risk of morbidity/mortality and the goals of therapy. The currently available second-line therapies for ITP provide potential for management of thrombocytopenia and bleeding symptoms with medical therapy or surgical intervention potentially offering long-term remission. All therapies are associated with potential side effects and necessary monitoring or modifications/risks and careful discussion of these is necessary to determine the optimal therapy for each patient. This review covers second-line therapies for ITP and discusses the currently available information on immunomodulatory second-line treatments for ITP.